KPC Pharmaceuticals Inc
SSE:600422
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
KPC Pharmaceuticals Inc (600422) under the Base Case is 9.82 CNY per share.
Compared with the current market price of 8.47 CNY, the stock appears
Undervalued by 14% .
The intrinsic value is calculated using the DCF method. The model mostly extends the recent record: revenue grows about -2% a year over the next five years, against -3% over the last five, and net margin stays near last year's 5.3%. If revenue grew at its five-year pace of -3%, the estimate would be about ¥6.54.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What KPC Pharmaceuticals Does
KPC Pharmaceuticals makes and sells medicines in China, with a strong focus on traditional Chinese medicine products along with some chemical drugs and related healthcare products. It develops, manufactures, and markets prescription medicines and over-the-counter products used for common conditions such as infections, pain, and cardiovascular or respiratory care. Its business is built around finished drug products rather than raw materials alone.
- Headquarters
- China CN
- Employees
- 5 072
- IPO date
- Dec 6, 2000
KPC Pharmaceuticals has no economic moat
KPC Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysisContinue Research
Decided on KPC Pharmaceuticals? Get an email when KPC Pharmaceuticals Inc reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one KPC Pharmaceuticals Inc stock?
The intrinsic value for
KPC Pharmaceuticals Inc (600422) under the Base Case is 9.82 CNY.
Is KPC Pharmaceuticals Inc stock undervalued or overvalued?
Compared with the current market price of 8.47 CNY, the stock appears Undervalued by 14% .